MWA
ZYNE

Marshall Wace Asia’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Marshall Wace Asia’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-82,249
Closed -$1.65M – 100
2017
Q1 		$1.65M Buy
+82,249
New +$1.63M 0.1% 59

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Marshall Wace Asia's ZYNE Position: Q2 2017 in Review

Marshall Wace Asia sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2017, closing a stake of 82,249 shares — an estimated $1.65M sold.

Marshall Wace Asia first reported a position in ZYNE in Q1 2017 and held it in 1 quarter. The position peaked at $1.65M in Q1 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q2 2017.

  • Marshall Wace Asia reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Marshall Wace Asia sold 82,249 Zynerba Pharmaceuticals, Inc shares in Q2 2017, an estimated $1.65M.
  • Marshall Wace Asia first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 1 quarter.
  • Marshall Wace Asia's Zynerba Pharmaceuticals, Inc position peaked at $1.65M in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2017.

Based on Marshall Wace Asia's 13F filing for Q2 2017, filed 4 Aug 2017.